From identifying key biomarkers to a diverse pipeline of investigational therapies, we aspire to lead advancements in cancer care.
Find out more about which tumor types are being studied in currently enrolling late-stage clinical trials.
Learn more about some of the immune signals and pathways tumors exploit to avoid an immune response.
Discover a broad range of development platforms such as small molecules and bispecific antibodies.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.